You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
The DXRX marketplace, planned for launch in the fourth quarter of 2020, will provide a way for pharmaceutical companies, diagnostic firms, and laboratories to collaborate.
The Medicare Administrative Contractor's decision covers molecular diagnostic laboratory tests as predictive classifiers for non-small cell lung cancer.
The new rate applies to clinical diagnostic lab tests using high-throughput technologies that can process more than 200 specimens per day.
Under the guidance, group health plans and group and individual health insurers must cover diagnostic testing and other "certain related items and services."
The sponsors of the VALID Act say it's time to modernize outdated diagnostic regulations slowing down test access during a public health crisis.
The agency will reimburse at about $35.91 per test for CDC assays and about $51.31 per test for non-CDC assays.
A bi-weekly listing of recent local coverage determinations from Medicare Administrative Contractors.
The bipartisan bill is backed by more than 250 organizations, but ACMG remains opposed, arguing that ordering tests is part of the practice of medicine.
Medicare Administrative Contractor Palmetto released its final local coverage decision last year, and WPSIC has now aligned its coverage.
The final national coverage decision stipulates that NGS germline tests for assessing hereditary breast and ovarian cancer risk must have FDA's blessing.
Nearly 30,000 COVID-19 tests the UK sent to the US came back as void, according to the Telegraph.
Black principal investigators receive less favorable application scores when seeking US National Institutes of Health grants, the Chronicle of Higher Education reports.
New Scientist reports that both RNA and DNA may have been involved in the emergence of life on Earth.
In Nature this week: new Sperm-seq method enables crossover analysis, tumor-informed detection approach for minimal residual disease, and more.